Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination

• 收藏
• 分享

专利权人:

BioNTech Cell & Gene Therapies GmbH;TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gGmbH

发明人:

Sahin, Ugur,Reinhard, Katharina,Simon, Petra,Mroz, Karolina Anna,Hobohm, Kathleen

申请号：

AU2020203129

公开号：

AU2020203129A1

申请日:

2020.05.13

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

#$%^&*AU2020203129A120200604.pdf#####ABSTRACT The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/